

# CARDIAC MYOSIN INHIBITORS


## AS A TREATMENT FOR HCM



### HYPERTROPHIC CARDIOMYOPATHY (HCM)

is a genetic condition that causes the heart muscle to thicken, making it harder for the heart to pump blood.

Previously, treatment only alleviated symptoms, but **NEW MEDICATIONS** like cardiac myosin inhibitors address the underlying cause.



The first cardiac myosin inhibitor was **APPROVED BY THE FDA** in 2022 to treat obstructive HCM.



These oral treatments **STRENGTHEN BLOOD FLOW** from the heart by relaxing the heart's contractions.

Cardiac myosin inhibitors allow patients and providers to **TAILOR TREATMENT TO INDIVIDUAL NEEDS AND PREFERENCES.**

